Roche’s Alecensa approved in China
Roche AGs ALK blocker Alecensa (alectinib) has been granted market approval by China National Drug Administration as first line NSCLC monotherapy in patients with ALK-positive non small cell lung cancer (NSCLC)
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1116 entries already.
Entries by Thomas Gabrielczyk
Pfizer partners with Biontech in US$425m deal
/in News/by Thomas GabrielczykBioNTech AG has partnered with Pfizer to develop a mRNA-based flu vaccine.
New lupus target unraveled
/in News/by Thomas GabrielczykEGFR agonists support the protective effect of Langerhans against UV-induced damage of skin cells, a hallmark of lupus erythematosus and other autoimmune and dermatologic conditions, a team of US and […]
Small molecule restores liver regeneration
/in News/by Thomas GabrielczykA team of Scots, Belgian and Spanish researchers claim they have found a target to prevent failure of liver regeneration following intoxination or acute injury.
Orchard Therapeutics raise US-$150m
/in News/by Thomas GabrielczykLondon-headquartered gene therapy Orchard Therapeutics has closed a US-$150m series C financing round to push MAAs and BLAs of three late-stage gene therapies by 2021.
Artios Pharma raise 85m in Series B round
/in News/by Thomas GabrielczykLife Sciences Partners and Andera Partners together with Pfizer Ventures and Novartis Venture Fund have put 85m into the cancer drug development company Artios Pharma Ltd.
Researchers remyelinate neurons
/in News/by Thomas GabrielczykGerman neurogenetics at the Max-Planck-Institute for Experimental Medicine have cured the rare incurable hereditary Charcot-Marie-Tooth disease by simply supplementing the food of mice carrying the disease-causing duplication of the PMP22 gene with […]
Switch for osteoporosis and obesity
/in News/by Thomas GabrielczykGerman researchers have found a molecular switch that determines whether mesenchymal fibroblasts differentiate into fat- or bone-forming cells opening the avenue to modulation of the processes.
Roche presents biomarker test to identify NSCLC responders to Tecentriq
/in News/by Thomas GabrielczykResearchers at Roche’s US arms Genentech and Foundation Medicine Inc. (FMI) presented a liquid biopsy test that can be used to identify NSCLC patients who respond to Roche’s PD-L1 blocker […]
Boehringer Ingelheim starts gene therapy collaboration for cystic fibrosis
/in News/by Thomas GabrielczykGerman pharma company and CDMO Boehringer Ingelheim (BI) steps into the lucrative field of gene therapy. Together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), BI aims at developing replacement […]